THIRD-PARTY REVIEW PROVISIONS OF S 1477 REMAIN CONCERN, KENNEDY STAFFER SAYS;FDA COMMISSIONER TERM LIMITS LIKELY WILL TARGET KESSLER, STAFFER PREDICTS
Third-party review mandates in Sen. Kassebaum's (R-Kan.) FDA reform bill (S 1477) are "more worrisome" than the bill's provision for expedited approval for drugs cleared in the European Union, said Pearl O'Rourke, MD, Robert Wood Johnson fellow to Sen. Kennedy (D-Mass.) on the Labor & Human Resources Committee. She made her remarks at the University of North Carolina-Chapel Hill's Center for Pharmaceutical Outcomes Research conference March 31.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth